Navigation Links
PROLOR Biotech Announces Initiation of Phase I Clinical Trial for its Long-Acting Growth Hormone
Date:9/21/2009

NES-ZIONA, Israel, Sept. 21 /PRNewswire-FirstCall/ -- PROLOR Biotech, Inc. (OTC Bulletin Board: PBTH) formerly Modigene Inc., today announced the initiation of a Phase I clinical trial of its long-acting human growth hormone drug candidate hGH-CTP.

hGH-CTP is being developed to provide growth hormone deficient adults and children with the option to replace the multiple injections per week that are currently required with a once-weekly or bi-monthly injection. The initiation of the trial follows a successful safety and immunogenicity study of hGH-CTP in primates and regulatory approvals by the IRB committee of the Tel-Aviv Medical Center and the Israeli Ministry of Health.

The Phase I trial is a randomized, double-blinded, placebo-controlled, single-dose, dose-escalating study to evaluate the safety, tolerability, and pharmacokinetic and pharmacodynamic properties of hGH-CTP in 24 healthy volunteers. It will be conducted at the Early-Phase Clinical Pharmacology Unit located at the Tel-Aviv Medical Center.

"The initiation of a Phase I clinical trial of our long-acting hGH-CTP represents an important milestone for PROLOR," said Dr. Avri Havron, CEO of PROLOR. "We were delighted with the results of our hGH-CTP studies in primates, which showed that hGH-CTP had an excellent half-life and biological activity and was safe at all doses tested without any signs of immunogenicity. We are now eager to obtain data on its bioactivity in humans."

Dr. Havron continued, "This trial is being conducted at the Early-Phase Clinical Pharmacology Unit at the Tel-Aviv Sourasky Medical Center, a top-notch facility that has a successful track record of conducting more than 250 clinical studies for leading global pharmaceutical and biotech companies in a variety of clinical areas. We look forward to completing the Phase I trial so that we can move ahead with the further clinical develo
'/>"/>

SOURCE PROLOR Biotech, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. PROLOR Biotech Awarded Two U.S. Patents for Its Longer-Acting Human Growth Hormone and Longer-Acting Erythropoietin
2. PROLOR Biotech Announces $10 Million Preferred Stock Line From Members of The Frost Group
3. PROLOR Biotech Acquires License Option from Yeda for Development of Long-Acting Anti-Obesity Drug
4. PROLOR Biotech to Present at the UBS 2009 Global Life Sciences Conference
5. Spherix Shareholders Support Companys Focus on Naturlose, Biotechnology
6. China Kangtai Cactus Biotech Files 2nd Quarter 2007 10QSB and Announces Unaudited Quarterly Results
7. ISI Increases West Coast Life Science and Biotech Support for Emerging Companies with Expansion in San Francisco and San Diego
8. Amyris Biotechnologies Co-Founder Neil Renninger Named to Technology Reviews Prestigious TR35 List of Top Young Innovators
9. Finkelstein Thompson LLP Announces GPC Biotech AG Investigation
10. Operon Biotechnologies and DNA2.0 Announce Co-Marketing and Technology Development Partnership
11. Clinical Data Acquires Epidauros Biotechnologie AG, Significantly Enhancing Proprietary Genetic Biomarker Portfolio
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... Switzerland (PRWEB) January 22, 2015 Selexis ... characterized mammalian Research Cell Banks (RCBs) used for drug ... Research Cell Banks will include Next-Generation Sequencing ... genetic architecture de-risks biologic manufacturing by ensuring the integrity ...
(Date:1/22/2015)... 22, 2015   Cypher Genomics, Inc., the ... SQNM ), the leading molecular diagnostics ... generation noninvasive prenatal tests (NIPT). Through this agreement, ... Mantis™, to advance analysis of clinically-relevant fetal sub-chromosomal ...
(Date:1/22/2015)...  Derma Sciences, Inc. (Nasdaq: DSCI ), ... care, announces that AMNIOEXCEL® and AMNIOMATRIX®, amniotic allografts ... the Premier, Inc. Regenerative Skin Grafting contract portfolio. ... and AMNIOMATRIX® product lines, which continue to be ...
(Date:12/24/2014)... , Dec. 24, 2014 PlasmaTech Biopharmaceuticals, Inc. (NASDAQ: ... areas, announced the closing of an underwritten public offering of ... to an aggregate 3,500,000 shares of common stock, at an ... The warrants have a per share exercise price of $5.00, ...
Breaking Biology Technology:Selexis Generated Research Cell Banks Now Fully Sequenced Using Next-Generation Sequencing 2Cypher Genomics and Sequenom Announce Development Agreement 2Cypher Genomics and Sequenom Announce Development Agreement 3Cypher Genomics and Sequenom Announce Development Agreement 4Derma Sciences Expands Access of its AMNIOTIC TISSUE Product Line with New Premier, Inc. Agreement 2Derma Sciences Expands Access of its AMNIOTIC TISSUE Product Line with New Premier, Inc. Agreement 3Derma Sciences Expands Access of its AMNIOTIC TISSUE Product Line with New Premier, Inc. Agreement 4Derma Sciences Expands Access of its AMNIOTIC TISSUE Product Line with New Premier, Inc. Agreement 5PlasmaTech Biopharmaceuticals, Inc. Announces Closing of Public Offering 2PlasmaTech Biopharmaceuticals, Inc. Announces Closing of Public Offering 3
... Community...promotes entertainment everywhere on any device , ,MADISON, ... the sale of the companys desktop products group for ... transaction is now complete and Sony Pictures Digitals Executive ... keep the companys employee base in Madison and in ...
... become leader in alternative energy , ,Madison, WI ... purchase agreement with two developers that will build three ... produced in Wisconsin by 400%. , ,Under the agreement, ... Midwest Wind Energy, LLC, based in Chicago, will provide ...
... Build it, and they will come is an acceptable strategy ... diamond in an Iowa cornfield, but its not normally the ... team of partners in place, the La Crosse Health Science ... transfer Field of Dreams. , ,The $27 million, 168,000-square-foot center ...
Cached Biology Technology:Sony Completes Acquisition of Sonic Foundry 2Sony Completes Acquisition of Sonic Foundry 3WE Energies Is Not Letting Wind Power Blow Away 2La Crosse Health Science Center is an Evolving Example of Collaboration 2La Crosse Health Science Center is an Evolving Example of Collaboration 3
(Date:1/22/2015)... 2015 Research and Markets ( http://www.researchandmarkets.com/research/wxdglm/global_wearable ... "Global Wearable Technologies Market and Applications, Opportunities, Industry ... Forecast 2014-2020" report to their offering. ... that can be worn on the user,s body ...
(Date:12/22/2014)... DUBLIN , Dec. 22, 2014 Research and ... the addition of the "The Global Watermarking ... http://photos.prnewswire.com/prnh/20130307/600769 ... global digital media watermarking and fingerprinting markets. Watermarking ...
(Date:12/19/2014)... 18, 2014   LaunchKey , the first decentralized mobile ... Internet of Things era, today announced the close of ... was led by Metamorphic Ventures with participation from ENIAC ... and others.  LaunchKey has raised $4 million to date, ...
Breaking Biology News(10 mins):Global Wearable Technologies Market and Applications, Opportunities, Industry Analysis, Segmentation, Size, Growth, Share, Overview, Trends and Forecast 2014-2020 2The Global Watermarking and Fingerprinting Markets 2LaunchKey Raises $3 Million in Additional Funding Led by Metamorphic Ventures 2LaunchKey Raises $3 Million in Additional Funding Led by Metamorphic Ventures 3
... History Survey have found that overall, concentrations of arsenic, selenium, ... Illinois River do not appear to be a health concern ... of the study have been published in the journal ... fillets was below the US Food and Drug Administration Action ...
... Hebrew university of Jerusalem have created a molecule that ... dementia or Alzheimer,s disease. Recent studies indicate that ... and non-diabetics are a risk factor for the development ... function. Diabetics have also been found to have twice ...
... in adulthood will be investigated as part of a major ... The 7.4 million programme, funded by the European Commission, ... eat and the types of food we choose. The ... eating habits develop and the influence of hunger, emotions, stress ...
Cached Biology News:Research shows arsenic, mercury and selenium in Asian carp not a health concern to most 2New molecule protects brain from detrimental effects linked to diabetes and high blood sugar 280 million SEK study seeks to explain what drives our appetites 2
... be used with all 96-well ... stacking of covered plates ... with automated systems ... are available for use with ...
... Two sizes available for use with 96- or 384-well ... 96 for ease of location on 96-tube plates ... the skirt of the plate* Efficient sealing is ... in conjunction with screw or clip-down hot lid thermal ...
... reagent is intended for use as a wash ... Michels Transport Fluid is useful for transportation of ... for immunofluorescence studies. Samples may remain in ... room temperature. Michels Transport Fluid is not ...
... HistoMark Biotin Streptavidin-HRP Systems provide rapid, ... intracellular antigens in frozen or paraffin-embedded ... These systems also facilitate double or ... be performed simultaneously with primary antibodies ...
Biology Products: